Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGF vs GFF triple vs dual therapy in COPD with elevated cardiopulmonary risk
jRCT2061230113Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Randomised trial of BGF MDI HFO and fluticasone propionate + formoterol fumarate + glycopyrronium bromide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Time to first severe cardiac or COPD event and Cardiopulmonary outcomes comparison. Started Apr 2024; status: recruiting.
02
Drugs
BGF MDI HFOfluticasone propionate + formoterol fumarate + glycopyrronium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2061230113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230113.